NCT00462202View on ClinicalTrials.gov

Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong

PHASE3TerminatedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Diabetic Nephropathy
Interventions
DRUG

sulodexide

Trial Locations (1)

3168

Monash Medical Center, Melbourne

Sponsors
All Listed Sponsors
collaborator

Collaborative Study Group (CSG)

NETWORK

lead

Keryx Biopharmaceuticals

INDUSTRY